Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry
vs
history
Cash to Debt No Debt
RGEN's Cash to Debt is ranked higher than
98% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: 58.56 vs. RGEN: No Debt )
Ranked among companies with meaningful Cash to Debt only.
RGEN' s Cash to Debt Range Over the Past 10 Years
Min: 63.71  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.88
RGEN's Equity to Asset is ranked higher than
81% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. RGEN: 0.88 )
Ranked among companies with meaningful Equity to Asset only.
RGEN' s Equity to Asset Range Over the Past 10 Years
Min: 0.83  Med: 0.92 Max: 0.98
Current: 0.88
0.83
0.98
Interest Coverage 454.76
RGEN's Interest Coverage is ranked lower than
56% of the 365 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. RGEN: 454.76 )
Ranked among companies with meaningful Interest Coverage only.
RGEN' s Interest Coverage Range Over the Past 10 Years
Min: 194.44  Med: 443.80 Max: 3988
Current: 454.76
194.44
3988
F-Score: 8
Z-Score: 31.00
M-Score: -2.76
WACC vs ROIC
10.12%
16.17%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 15.02
RGEN's Operating margin (%) is ranked higher than
83% of the 730 Companies
in the Global Biotechnology industry.

( Industry Median: -77.71 vs. RGEN: 15.02 )
Ranked among companies with meaningful Operating margin (%) only.
RGEN' s Operating margin (%) Range Over the Past 10 Years
Min: -27.5  Med: 14.85 Max: 186.01
Current: 15.02
-27.5
186.01
Net-margin (%) 9.16
RGEN's Net-margin (%) is ranked higher than
79% of the 730 Companies
in the Global Biotechnology industry.

( Industry Median: -78.92 vs. RGEN: 9.16 )
Ranked among companies with meaningful Net-margin (%) only.
RGEN' s Net-margin (%) Range Over the Past 10 Years
Min: -19.38  Med: 12.03 Max: 192.3
Current: 9.16
-19.38
192.3
ROE (%) 6.66
RGEN's ROE (%) is ranked higher than
82% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -32.89 vs. RGEN: 6.66 )
Ranked among companies with meaningful ROE (%) only.
RGEN' s ROE (%) Range Over the Past 10 Years
Min: -6.01  Med: 7.78 Max: 82.79
Current: 6.66
-6.01
82.79
ROA (%) 5.75
RGEN's ROA (%) is ranked higher than
86% of the 939 Companies
in the Global Biotechnology industry.

( Industry Median: -28.03 vs. RGEN: 5.75 )
Ranked among companies with meaningful ROA (%) only.
RGEN' s ROA (%) Range Over the Past 10 Years
Min: -5.6  Med: 6.72 Max: 75.79
Current: 5.75
-5.6
75.79
ROC (Joel Greenblatt) (%) 40.75
RGEN's ROC (Joel Greenblatt) (%) is ranked higher than
89% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. RGEN: 40.75 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
RGEN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -97.28  Med: 46.87 Max: 1148.92
Current: 40.75
-97.28
1148.92
Revenue Growth (3Y)(%) 7.70
RGEN's Revenue Growth (3Y)(%) is ranked higher than
59% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. RGEN: 7.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
RGEN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -41.2  Med: 21.90 Max: 45.6
Current: 7.7
-41.2
45.6
EBITDA Growth (3Y)(%) 4.20
RGEN's EBITDA Growth (3Y)(%) is ranked higher than
58% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. RGEN: 4.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
RGEN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -64.8  Med: 4.45 Max: 109.7
Current: 4.2
-64.8
109.7
EPS Growth (3Y)(%) -14.60
RGEN's EPS Growth (3Y)(%) is ranked lower than
62% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: -5.10 vs. RGEN: -14.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
RGEN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 2.15 Max: 108
Current: -14.6
0
108
» RGEN's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-06)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

RGEN Guru Trades in Q2 2015

RS Investment Management 1,382,573 sh (New)
Jim Simons 950,104 sh (+10.46%)
John Burbank Sold Out
Paul Tudor Jones 7,496 sh (-25.75%)
» More
Q3 2015

RGEN Guru Trades in Q3 2015

Joel Greenblatt 25,388 sh (New)
Paul Tudor Jones 9,531 sh (+27.15%)
RS Investment Management 1,411,394 sh (+2.08%)
Jim Simons 874,790 sh (-7.93%)
» More
Q4 2015

RGEN Guru Trades in Q4 2015

Paul Tudor Jones 12,810 sh (+34.40%)
RS Investment Management Sold Out
Joel Greenblatt 23,952 sh (-5.66%)
Jim Simons 782,104 sh (-10.60%)
» More
Q1 2016

RGEN Guru Trades in Q1 2016

Columbia Wanger 604,635 sh (New)
Chuck Royce 100,000 sh (New)
Joel Greenblatt 37,195 sh (+55.29%)
Jim Simons 982,404 sh (+25.61%)
Paul Tudor Jones 9,490 sh (-25.92%)
» More
» Details

Insider Trades

Latest Guru Trades with RGEN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:AVXS, NAS:ADRO, NAS:CHRS, NAS:DERM, NAS:BGNE, NAS:FWP, NAS:AMAG, NAS:CEMP, NAS:EDIT, NAS:CXRX, OTCPK:CMVLF, NAS:MGNX, OTCPK:AUCL, OTCPK:TYMI, OTCPK:BVNRY, NAS:KERX, NAS:FOLD, NAS:TBPH, NAS:SRPT, NAS:ANIK » details
Traded in other countries:RGN.Germany,
Repligen Corp is a life sciences company engaged in the development, manufacture & sale of consumable bioprocessing products for life sciences companies & biopharmaceutical manufacturing companies. It also supplies growth factor products.

Repligen Corp was incorporated in May 1981, under the laws of the State of Delaware. The Company is a life sciences company that develops, manufactures and markets consumable bioprocessing products for life sciences companies and biopharmaceutical manufacturing companies. It is also engaged in the manufacture of both native and recombinant forms of Protein A, critical reagents used in biomanufacturing to separate and purify monoclonal antibodies, a type of biologic drug. The Company also supplies growth factor products used to increase cell culture productivity during the biomanufacturing process. In the burgeoning area of biomanufacturing technologies, it has developed and currently markets a series of OPUS or Open-Platform, User-Specified chromatography columns for use in clinical-scale manufacturing. The Company manufactures and sells Protein A and growth factors to life sciences companies under long-term supply agreements and sell its chromatography columns, as well as media and quality test kits, directly to biopharmaceutical companies or contract manufacturing organizations. It manufactures seven forms of commercial scale Protein A including native Protein A for life sciences companies under long-term supply agreements which expire between 2016 and 2021. On December 28, 2012, it out-licensed its SMA program, led by RG3039, to Pfizer Inc. On January 21, 2014, it also out-licensed its histone deacetylase inhibitor portfolio which includes the Friedreich's ataxia program, to BioMarin Pharmaceuticals Inc., or BioMarin. The Company has developed RG1068, a synthetic human hormone for the improved detection of pancreatic duct abnormalities in combination with magnetic resonance imaging in patients with pancreatitis and potentially other pancreatic diseases. It conducts manufacturing in Waltham and at its facility in Lund, Sweden. It sells its bioprocessing products through direct sales force to partners such as GE Healthcare, EMD Millipore, Sigma Aldrich and to distributors in certain foreign markets.

Ratios

vs
industry
vs
history
P/E(ttm) 119.13
RGEN's P/E(ttm) is ranked lower than
84% of the 254 Companies
in the Global Biotechnology industry.

( Industry Median: 29.09 vs. RGEN: 119.13 )
Ranked among companies with meaningful P/E(ttm) only.
RGEN' s P/E(ttm) Range Over the Past 10 Years
Min: 3.19  Med: 58.92 Max: 99999999.99
Current: 119.13
3.19
99999999.99
PE(NRI) 119.13
RGEN's PE(NRI) is ranked lower than
85% of the 229 Companies
in the Global Biotechnology industry.

( Industry Median: 29.71 vs. RGEN: 119.13 )
Ranked among companies with meaningful PE(NRI) only.
RGEN' s PE(NRI) Range Over the Past 10 Years
Min: 3.19  Med: 58.92 Max: 99999999.99
Current: 119.13
3.19
99999999.99
Price/Owner Earnings (ttm) 440.00
RGEN's Price/Owner Earnings (ttm) is ranked lower than
92% of the 130 Companies
in the Global Biotechnology industry.

( Industry Median: 34.88 vs. RGEN: 440.00 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
RGEN' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 3.26  Med: 32.37 Max: 3202.31
Current: 440
3.26
3202.31
P/B 7.35
RGEN's P/B is ranked lower than
77% of the 1075 Companies
in the Global Biotechnology industry.

( Industry Median: 3.25 vs. RGEN: 7.35 )
Ranked among companies with meaningful P/B only.
RGEN' s P/B Range Over the Past 10 Years
Min: 1.42  Med: 2.83 Max: 12.19
Current: 7.35
1.42
12.19
P/S 10.94
RGEN's P/S is ranked higher than
55% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 12.77 vs. RGEN: 10.94 )
Ranked among companies with meaningful P/S only.
RGEN' s P/S Range Over the Past 10 Years
Min: 2.73  Med: 6.75 Max: 20.38
Current: 10.94
2.73
20.38
PFCF 82.15
RGEN's PFCF is ranked lower than
79% of the 147 Companies
in the Global Biotechnology industry.

( Industry Median: 27.27 vs. RGEN: 82.15 )
Ranked among companies with meaningful PFCF only.
RGEN' s PFCF Range Over the Past 10 Years
Min: 3.2  Med: 36.19 Max: 756.91
Current: 82.15
3.2
756.91
POCF 71.15
RGEN's POCF is ranked lower than
80% of the 205 Companies
in the Global Biotechnology industry.

( Industry Median: 22.90 vs. RGEN: 71.15 )
Ranked among companies with meaningful POCF only.
RGEN' s POCF Range Over the Past 10 Years
Min: 3.14  Med: 34.16 Max: 99999999.99
Current: 71.15
3.14
99999999.99
EV-to-EBIT 75.66
RGEN's EV-to-EBIT is ranked lower than
85% of the 295 Companies
in the Global Biotechnology industry.

( Industry Median: 20.49 vs. RGEN: 75.66 )
Ranked among companies with meaningful EV-to-EBIT only.
RGEN' s EV-to-EBIT Range Over the Past 10 Years
Min: -633.3  Med: 13.35 Max: 650.3
Current: 75.66
-633.3
650.3
EV-to-EBITDA 54.44
RGEN's EV-to-EBITDA is ranked lower than
81% of the 319 Companies
in the Global Biotechnology industry.

( Industry Median: 17.75 vs. RGEN: 54.44 )
Ranked among companies with meaningful EV-to-EBITDA only.
RGEN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -329.8  Med: 13.80 Max: 466
Current: 54.44
-329.8
466
Shiller P/E 87.04
RGEN's Shiller P/E is ranked lower than
63% of the 54 Companies
in the Global Biotechnology industry.

( Industry Median: 56.77 vs. RGEN: 87.04 )
Ranked among companies with meaningful Shiller P/E only.
RGEN' s Shiller P/E Range Over the Past 10 Years
Min: 44.76  Med: 79.46 Max: 470
Current: 87.04
44.76
470
Current Ratio 6.65
RGEN's Current Ratio is ranked higher than
62% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. RGEN: 6.65 )
Ranked among companies with meaningful Current Ratio only.
RGEN' s Current Ratio Range Over the Past 10 Years
Min: 4.48  Med: 8.74 Max: 44.57
Current: 6.65
4.48
44.57
Quick Ratio 5.30
RGEN's Quick Ratio is ranked higher than
56% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.24 vs. RGEN: 5.30 )
Ranked among companies with meaningful Quick Ratio only.
RGEN' s Quick Ratio Range Over the Past 10 Years
Min: 4.2  Med: 8.44 Max: 43.88
Current: 5.3
4.2
43.88
Days Inventory 156.05
RGEN's Days Inventory is ranked lower than
60% of the 444 Companies
in the Global Biotechnology industry.

( Industry Median: 128.57 vs. RGEN: 156.05 )
Ranked among companies with meaningful Days Inventory only.
RGEN' s Days Inventory Range Over the Past 10 Years
Min: 87.98  Med: 145.49 Max: 166.4
Current: 156.05
87.98
166.4
Days Sales Outstanding 52.26
RGEN's Days Sales Outstanding is ranked higher than
58% of the 607 Companies
in the Global Biotechnology industry.

( Industry Median: 62.37 vs. RGEN: 52.26 )
Ranked among companies with meaningful Days Sales Outstanding only.
RGEN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 6.73  Med: 22.84 Max: 49.37
Current: 52.26
6.73
49.37
Days Payable 49.09
RGEN's Days Payable is ranked lower than
56% of the 444 Companies
in the Global Biotechnology industry.

( Industry Median: 57.77 vs. RGEN: 49.09 )
Ranked among companies with meaningful Days Payable only.
RGEN' s Days Payable Range Over the Past 10 Years
Min: 24.96  Med: 67.66 Max: 161.29
Current: 49.09
24.96
161.29

Valuation & Return

vs
industry
vs
history
Price/Net Cash 18.45
RGEN's Price/Net Cash is ranked lower than
82% of the 739 Companies
in the Global Biotechnology industry.

( Industry Median: 5.19 vs. RGEN: 18.45 )
Ranked among companies with meaningful Price/Net Cash only.
RGEN' s Price/Net Cash Range Over the Past 10 Years
Min: 1.93  Med: 5.81 Max: 30.8
Current: 18.45
1.93
30.8
Price/Net Current Asset Value 10.92
RGEN's Price/Net Current Asset Value is ranked lower than
75% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 4.83 vs. RGEN: 10.92 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
RGEN' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.69  Med: 4.67 Max: 18.34
Current: 10.92
1.69
18.34
Price/Tangible Book 9.29
RGEN's Price/Tangible Book is ranked lower than
76% of the 1012 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. RGEN: 9.29 )
Ranked among companies with meaningful Price/Tangible Book only.
RGEN' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.52  Med: 3.48 Max: 15.04
Current: 9.29
1.52
15.04
Price/Projected FCF 3.85
RGEN's Price/Projected FCF is ranked lower than
52% of the 201 Companies
in the Global Biotechnology industry.

( Industry Median: 3.44 vs. RGEN: 3.85 )
Ranked among companies with meaningful Price/Projected FCF only.
RGEN' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.69  Med: 1.10 Max: 6.15
Current: 3.85
0.69
6.15
Price/Median PS Value 1.62
RGEN's Price/Median PS Value is ranked lower than
76% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. RGEN: 1.62 )
Ranked among companies with meaningful Price/Median PS Value only.
RGEN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.29  Med: 1.12 Max: 10.04
Current: 1.62
0.29
10.04
Price/Graham Number 7.01
RGEN's Price/Graham Number is ranked lower than
80% of the 214 Companies
in the Global Biotechnology industry.

( Industry Median: 2.88 vs. RGEN: 7.01 )
Ranked among companies with meaningful Price/Graham Number only.
RGEN' s Price/Graham Number Range Over the Past 10 Years
Min: 0.54  Med: 3.06 Max: 11.18
Current: 7.01
0.54
11.18
Earnings Yield (Greenblatt) (%) 1.37
RGEN's Earnings Yield (Greenblatt) (%) is ranked higher than
78% of the 1169 Companies
in the Global Biotechnology industry.

( Industry Median: -9.30 vs. RGEN: 1.37 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
RGEN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.2  Med: 2.75 Max: 9.9
Current: 1.37
0.2
9.9

More Statistics

Revenue (TTM) (Mil) $87.81
EPS (TTM) $ 0.24
Beta1.14
Short Percentage of Float10.60%
52-Week Range $20.07 - 39.17
Shares Outstanding (Mil)33.64
» More Articles for RGEN

Headlines

Articles On GuruFocus.com
Repligen Corp. Reports Operating Results (10-Q) Feb 09 2011 
Repligen Corp. Reports Operating Results (10-Q) Nov 02 2010 
Repligen Corp. Reports Operating Results (10-Q) Aug 05 2010 
Repligen Corp. Reports Operating Results (10-Q) Feb 04 2010 
Repligen Corp. Reports Operating Results (10-Q) Nov 05 2009 
Repligen Corp. Reports Operating Results (10-Q) Feb 06 2009 

More From Other Websites
Repligen to Report Second Quarter 2016 Financial Results Jul 27 2016
Repligen to Report Second Quarter 2016 Financial Results Jul 27 2016
Repligen Corp. – Value Analysis (NASDAQ:RGEN) : July 1, 2016 Jul 01 2016
Repligen (RGEN) in Focus: Stock Adds 6.9% in Session Jun 30 2016
Repligen Corp. breached its 50 day moving average in a Bullish Manner : RGEN-US : June 30, 2016 Jun 30 2016
Repligen to Present at Jefferies 2016 Healthcare Conference Jun 02 2016
Repligen to Present at Jefferies 2016 Healthcare Conference Jun 02 2016
Repligen to Participate in 13th Annual Craig-Hallum Institutional Investor Conference May 26 2016
Repligen to Participate in 13th Annual Craig-Hallum Institutional Investor Conference May 26 2016
REPLIGEN CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements... May 24 2016
REPLIGEN CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events,... May 20 2016
Repligen Announces Pricing of $100 Million of 2.125% Convertible Senior Notes due 2021 May 19 2016
Repligen Announces Pricing of $100 Million of 2.125% Convertible Senior Notes due 2021 May 19 2016
Repligen Announces Proposed Public Offering of $100 Million of Convertible Senior Notes due 2021 May 18 2016
Repligen Announces Proposed Public Offering of $100 Million of Convertible Senior Notes due 2021 May 18 2016
REPLIGEN CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Submission of Matters... May 12 2016
Repligen Corp. :RGEN-US: Earnings Analysis: Q1, 2016 By the Numbers May 10 2016
Edited Transcript of RGEN earnings conference call or presentation 5-May-16 12:30pm GMT May 05 2016
Repligen tops 1Q revenue forecasts May 05 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)